Tumor plasticity driven by continual stepwise targeting of AR has garnered recent attention and may lead to AR negative cells driven by fibroblast growth factor (FGF) or neuroendocrine transdifferentiation mechanisms [9,10,11,12]. Here, AR is linked to neoplasm.